Angelini Pharma and Quiver Bioscience Partner on AI-Powered Genetic Epilepsy Research
Angelini Pharma and Quiver Bioscience have entered a multi-year research and licensing agreement to develop AI-driven therapies for genetic epilepsies. The partnership grants Angelini exclusive global rights to future drug targets identified through Quiver’s platform.